Dermapharm Holding SEFRA:DMP 87 Days Payable is 97.90 as of Mar. 2026, which is 93% above its 10-year median of 50.81. GuruFocus rates FRA:DMP with a GF Score™ of 87/100 and a GF Value™ of €39.11 (Modestly Overvalued). The stock has 9 warning signs investors should review. Among 920 Drug Manufacturers companies, Dermapharm Holding SE ranks better than 53.48% on this metric.
Dermapharm Holding SE Days Payable Historical Data
* Premium members only.
The historical data trend for Dermapharm Holding SE's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:DMP vs ZTS, UTHR, VTRS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Dermapharm Holding SE's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dermapharm Holding SE Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dermapharm Holding SE's Days Payable distribution charts can be found below:
* The bar in red indicates where Dermapharm Holding SE's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Dermapharm Holding SE's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dermapharm Holding SE (FRA:DMP) has a Days Payable of 97.90 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Dermapharm Holding SE and its competitors. This is 93% above median its historical median of 50.81. Over the past decade, Dermapharm Holding SE's Days Payable has ranged from 31.98 to 97.33. According to the industry distribution chart, Dermapharm Holding SE ranks #428 out of 920 companies in the Drug Manufacturers industry, placing it in the top 46.5%.
Is Dermapharm Holding SE's Days Payable too high?
Dermapharm Holding SE's current Days Payable of 97.90 is 93% above median its 10-year median of 50.81. Over the past 10 years, this metric has ranged from a low of 31.98 to a high of 97.33. The Drug Manufacturers industry median Days Payable is 90.84. Dermapharm Holding SE's value of 97.90 is 7.8% above this industry median. Based on the distribution chart, Dermapharm Holding SE ranks #428 out of 920 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Dermapharm Holding SE has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dermapharm Holding SE's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Dermapharm Holding SE ranks #428 out of 920 companies for Days Payable. This puts Dermapharm Holding SE in the upper half of its industry. The industry median Days Payable is 90.84. Dermapharm Holding SE's value of 97.90 is 7.8% above this benchmark. Historically, Dermapharm Holding SE's own Days Payable has ranged from 31.98 to 97.33 over the past decade. While the company's 10-year median is 50.81 vs. the industry median of 90.84, Dermapharm Holding SE has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dermapharm Holding SE's current Days Payable of 97.90 is 7.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Dermapharm Holding SE and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dermapharm Holding SE's current Days Payable is 97.90, which is 93% above median its own 10-year median of 50.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dermapharm Holding SE stock overvalued right now?
Based on GuruFocus' analysis, Dermapharm Holding SE (FRA:DMP) is currently considered Modestly Overvalued. The stock's GF Value™ is €39.11, compared to a current price of €46.25 — trading 18.3% above its estimated fair value. The current Days Payable is 97.90, which is 93% above median its 10-year median of 50.81 and 7.8% above the Drug Manufacturers industry median of 90.84. Dermapharm Holding SE's overall GF Score™ is 87/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Dermapharm Holding SE (FRA:DMP), the current Days Payable is 97.90 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dermapharm Holding SE (FRA:DMP) Overvalued in 2026?
Based on GuruFocus' analysis, Dermapharm Holding SE stock appears to be overvalued.
The current stock price of €46.25 is trading 18.3% above its estimated GF Value™ of €39.11.
GuruFocus considers Dermapharm Holding SE to be Modestly Overvalued.
Key valuation signals for FRA:DMP:
Days Payable: 97.90 (93% above median its 10-year median of 50.81)
GF Value™: €39.11 vs. price of €46.25 (18.3% above fair value)
Industry Position: 7.8% above the Drug Manufacturers median (#428 of 920)
No single metric tells the full story. See the FRA:DMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals, which drive key revenue, Other healthcare products, and Parallel import business. The Branded pharmaceuticals segment covers numerous product areas through a wide variety of items sold under reputable brand names.
87GF Score
Get the complete analysis for FRA:DMP
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:DMP has been successfully added to your 
